Artificial intelligence systems are beginning to function as “co-scientists” in cancer research, generating drug candidates, prioritizing immunotherapy targets, and guiding experimental design.

2020 Meetings Abstracts: AACR Special Conference on Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies January 9–12, 2020; San Diego, CA ...

Mitochondrial glutathione import via SLC25A39 supports breast cancer metastasis by linking glutathione availability to ATF4-driven integrated stress response signaling during early metastatic ...

Neuronal pentraxin 1 (NPTX1) is identified as a therapeutically druggable driver of pancreatic cancer metastatic colonization through its action on the receptor AMIGO2, which promotes HIF-1α nuclear ...

Abstract. Binding of steroid hormones to their cognate receptors regulates the growth of most prostate and breast cancers. We hypothesized that CYP11A inhibition might halt the synthesis of all ...

Abstract. Immunogenic cell death (ICD) is a form of apoptosis that kills susceptible populations of cancer cells while teaching the immune system to attack the remaining resistant cells.

1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. 3Department of Urology, James Buchanan ...

Creighton University School of Medicine, Omaha, NE.

1Department of Cell Growth and Tumor Regulation, Proteo-Science Center, Ehime University, Toon, Japan. Search for other works by this author on: 2Laboratory of Molecular Pharmacology & Developmental ...

Infrequently mutated genes comprise most of the mutational burden in breast tumors but are poorly understood. In vivo CRISPR screening identified functional tumor suppressors that converged on ...

22Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, ...

The combination of anti-TROP2 ADCs with PD-(L)1 inhibitors represents a promising therapeutic strategy, merging targeted therapy with immunotherapy to improve treatment outcomes. Clinical trials are ...